Oslo, 11 November 2024) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery.
The company is pleased to announce the successful completion of its Early Access program for the new MiraQ™ INTUI software platform. The official product launch is set for December 13 at the International Coronary Congress (ICC) in London.
Medistim’s devices for Transit Time Flow Measurement (TTFM) and High-Frequency Ultrasound (HFUS) are currently utilized in approximately 37% of the 700,000 coronary artery bypass graft (CABG) procedures performed worldwide each year. While TTFM is already the standard of care in many European and Asian countries, significant growth opportunities remain in key markets such as the United States. Driving global adoption and establishing routine use will depend on continued product innovation, focusing on enhanced user-friendliness and delivering greater clinical value.
Built on a cutting-edge, future-proof software architecture, INTUI sets a new standard for Medistim’s MiraQ™ technology. Its redesigned user interface is engineered to enhance procedural efficiency in surgery, offering simplified navigation, quicker access to critical data, and improved data interpretation—ultimately streamlining workflow and optimizing performance.
“Developed and tested in collaboration with an international team of cardiac surgeons, we are confident that INTUI offers advanced support for clinical decision-making, with the potential to improve patient safety and outcomes,” said Kari E. Krogstad, President and CEO of Medistim. “Our mission is to equip surgical teams with tools that simplify complex procedures, delivering exceptional ease of use. And this is just the beginning—we are excited to expand this technology to vascular applications in the near future.”
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, and Norway, in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com